Western medicine and Chinese patent medicine increased by about 15.4%.
Chen Jinfu, director of Ministry of Human Resources and Social Security Medical Insurance Department, introduced that the 20 17 version of the drug list consists of four parts: common cases, western medicines, Chinese patent medicines and Chinese herbal pieces. An example is the description and explanation of the drug list format, the specification of the name and dosage form, and the limited payment scope. Western medicine includes chemicals and biological products, Chinese patent medicines include Chinese patent medicines and ethnic medicines, and Chinese herbal medicines are not paid by the fund according to the exclusion law.
There are 2,535 western medicines and Chinese patent medicines, 339 more than the 2009 catalogue, with an increase of about 15.4%. Among them, western medicine 1297 and Chinese patent medicine 1238 (including ethnic medicine 88). Chinese herbal pieces have not been adjusted, and the provisions of the 2009 edition of the Drug Catalogue are still used.
Chen Jinxi said that all provinces (autonomous regions and municipalities) can make appropriate adjustments to some Class B drugs in the national medical insurance drug list according to regulations, and publish the medical insurance drug list of their own provinces (autonomous regions and municipalities). "We require that this work must be completed before July 3, 20 171day. After the release of drug lists in various provinces (autonomous regions and municipalities), all co-ordination areas should start implementing the new drug list within 1 month. "
New changes
When transferring drugs, new drugs should be given priority.
Chen Jinfu said that in the drug list work plan, "priority is given to new drugs with high clinical value, drugs with more local B adjustments, drugs for treating major diseases, drugs for children, emergency rescue drugs, and special drugs for occupational diseases." In the review, the expert group gave priority to the above drugs in strict accordance with the work plan, and paid attention to the connection with other relevant policies in the medical field.
New drug for treating pneumoconiosis
Chen Jinfu said that the 20 17 version of the drug list is applicable not only to the insured persons of basic medical insurance, but also to the insured persons of work-related injury insurance and maternity insurance, and the drugs used for work-related injury insurance are specially considered in the formulation of the list. On the one hand, the demand for drugs for special diseases such as occupational diseases is fully considered, and tetrandrine and other drugs for treating pneumoconiosis are added; On the other hand, the "Remarks" column of five drugs such as botulinum toxin A injection in the drug list is marked as "industrial injury insurance only". These drugs are only paid by the industrial injury insurance fund, but not by the basic medical insurance fund, which means that the scope of use of industrial injury insurance exceeds the basic medical insurance. In the next step, we will also guide the local authorities to timely include the treatment drugs with reliable efficacy in the local adjustment catalogue according to regulations.
Directory characteristics
Increase 9 1 drug variety for children.
Added 9 1 children's medicine. There are 540 kinds of drugs or dosage forms clearly suitable for children in the drug list, which increases the safety of children's medication.
Increase support for innovative drugs. The innovative development of the pharmaceutical industry is to develop and produce drugs with better quality, better curative effect and lower cost. Therefore, in the catalogue adjustment, the new drugs listed after 2009 will be the key evaluation targets, and the innovative drugs will be further tilted. From 2008 to the first half of 20 16, most of the innovative drugs and biological products approved by China were included in the drug list of version 20 17 or the scope of negotiated drugs, but only a few varieties were not included because they were not covered by medical insurance (vaccines) or had low clinical recognition.
Drugs that focus on major diseases. Commonly used drugs for the treatment of major diseases such as cancer, severe psychosis, hemophilia, diabetes, cardiovascular and cerebrovascular diseases are basically included in the drug list or the scope of negotiated drugs.
Vigorously support traditional Chinese medicine and ethnic medicine. On the basis of "paying equal attention to both Chinese and western medicine", we will increase support for Chinese medicine and ethnic medicine. Western medicine and Chinese patent medicine accounted for 5 1% and 49% respectively in the 20 17 version of the drug list, which was basically the same. Specializing in organizing minority medicine experts to evaluate Mongolian, Tibetan and other traditional ethnic medicines, 4 1 species of ethnic medicine was added, with an increase of 90%, which was significantly higher than other medicines.
Do a good job of connecting with 20 15 countries to negotiate drugs. Tenofovir, ectinib and gefitinib were all included in the drug list after expert review. In addition, vigorously support the basic drug system.
Drugs to be negotiated
Cancer drugs are included in the list to be negotiated.
Chen Jinfu said that some patents and exclusive drugs are clinically necessary and effective, but they are expensive. Listing them in the catalogue at the current market price may bring certain risks to the fund. It is necessary to explore the establishment of a negotiation access mechanism for these drugs, and formally include qualified drugs in the drug list after negotiation and appropriate price reduction.
In this catalogue review, 45 drugs to be negotiated were identified through expert consultation, expert selection and voting. Nearly half of these drugs are tumor-targeted drugs, covering common tumors such as leukemia, lung cancer, gastric cancer and colorectal cancer, and others are used for major diseases such as cardiovascular and cerebrovascular diseases, rare diseases and diabetes.
"In the next step, after confirming whether the relevant enterprises have the intention to negotiate, we will announce the list of negotiated drugs to the public and organize negotiations according to relevant procedures, and include the agreed varieties into the payment scope of the medical insurance fund to better protect the clinical drug demand of the insured personnel and ensure the smooth operation of the fund."
Further reading: How to buy insurance, which is good, and teach you how to avoid these "pits" of insurance.